http://seekingalpha.com/news/272033...ical-trials-in-japan?uprof=45&dr=1#email_link
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approvesPluristem Therapeutics' (NASDAQSTI) PLX-PAD cells for use in clinical trials in country. The clearance will enable the company to commence a Phase 2 study ofPLX-PAD in critical limb ischemia through Japan's accelerated regulatory pathway for regenerative medicine which allows for conditional, time-limited marketing approval after a single successful Phase 2 trial.The company intends to talk with the PDMA in Q4 to finalize the protocol. It expects to receive permission in Q4 to start the trial, which should commence in Q1 2016.
Any comments regarding the validity of these 2 articles?, page-5
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |